Thursday, 24 October 2013

Eli Lilly’s Profit Slides, Gets Priority Review for Ramucirumab « New Drug Approvals

Eli Lilly’s Profit Slides, Gets Priority Review for Ramucirumab « New Drug Approvals:

'via Blog this'

No comments:

Post a Comment